MANAGEMENT TEAM
Our team of highly experienced drug development specialists
Lena A. Basile, PhD, JD
CEO & Chairman of the Board- Education
- PhD, Columbia University
JD, University of Houston Law Center
- Experience
- Neumedicines founder
Over 20 years of scientific experience
Member of the CA & Patent Bars
7 years legal experience as a patent attorney
Secured >$76M in non-dilutive funding for Neumedicines
Elliot P. Friedman, MBA
President & Board Member- Education
- MBA, Sloan Management School of MIT
- Experience
- Chairman of management consulting company
CEO of Biotek Solutions which merged with Ventana Medical Systems & subsequently purchased by Roche Diagnostics for $3.2B
Cofounded PharmaPrint which reached a $300M market cap
Vladimir Vainstein, MD, MSc
CMO- Education
- MD, Hadassah Medical School of Hebrew University
MSc, Hadassah Medical School of Hebrew University
- Experience
- Board-certified hematologist
Over 10 years of experience in mechanism-based pharmacodynamics
Co-authored 20 scientific publications in peer-reviewed journals & co-inventor of 3 patents
Christopher Lawrence, PhD
VP, Development- Education
- PhD, Cambridge University
BSc, Newcastle University
- Experience
- Over 20 years of pharmaceutical & biotechnology experience
Occupied positions of increasing responsibility at Sanofi, Tularik, Amgen, Sunesis & Xencor
Advanced 14 small molecules & biologics into clinical trials
Co-authored 25 scientific publications, & co-inventor of 2 patents
Scott Buckel, PhD
VP, CMC Analytical/Regulatory- Education
- PhD, Purdue University
BS, University of Houston
- Experience
- Over 25 years of biotechnology experience
Occupied positions of increasing responsibility at Pittman-Moore, Parke-Davis, Amgen & Xencor
Supported the development of 25 biological drugs
Involved in the licensing of 6 biological drugs